UBS Group
DALS

UBS Group’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

UBS Group’s Portfolio DALS Stock Details DALS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,426
Closed -$55.7K – 10310
2023
Q2 		$55.7K Buy
5,426
+2,753
+103% +$28.1K ﹤0.01% 6406
2023
Q1 		$27.1K Buy
2,673
+1,897
+244% +$19.1K ﹤0.01% 6863
2022
Q4 		$7.68K Buy
776
+600
+341% +$5.91K ﹤0.01% 8872
2022
Q3 		$2K Hold
176
– – ﹤0.01% 9851
2022
Q2 		$2K Hold
176
– – ﹤0.01% 9706
2022
Q1 		$2K Hold
176
– – ﹤0.01% 9742
2021
Q4 		$2K Buy
+176
New +$1.72K ﹤0.01% 9880

UBS Group's DALS Position: Q3 2023 in Review

UBS Group sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 5,426 shares — an estimated $55.7K sold.

UBS Group first reported a position in DALS in Q4 2021 and held it in 7 quarters. The position peaked at $55.7K in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

  • UBS Group reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 5,426 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $55.7K.
  • UBS Group first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q4 2021 and held it in 7 quarters.
  • UBS Group's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $55.7K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.